The group's principal activity is to discover, develop and commercialize therapeutic and diagnostic products for applications in oncology and regenerative medicine and research tools for drug discovery. Product development programs are based upon three patented technologies: telomerase, human embryonic stem cells and nuclear transfer. Telomerase are the ends of chromosomes that protect chromosomes from degradation and act as a molecular clock for cellular aging. Human embryonic stem cells are potential source for the manufacture of replacement cells and tissues for organ repair applications in regenerative medicine. Nuclear transfer technology is developed to produce genetically matched cells that would not be rejected by the patient's immune system. This technology is used for repairing organs damaged by chronic degenerative disease. The group operates solely in the domestic market.
Executive Information
Name
Title
Email
Alexander Barkas
Chmn.
N/A
Calvin Harley
Chief Scientific Officer
N/A
David Earp
Chief Patent Counsel, Sr. VP - Business Development
